


Ludger

Glycan Analysis

Services



Glycan analysis for medical research and drug manufacturing

Consistently controlled and well-characterised glycosylation is a subject of concern during biopharmaceutical realisation and is recognised as a **critical quality attribute (CQA)**. It greatly increases drug complexity and heterogeneity, and can significantly influence **drug safety and efficacy**. Moreover, it is typically the single greatest contributor to drug batch-to-batch variability.

Analysis of glycosylation is important not only in biopharmaceutical development and manufacturing but also in **clinical and biological research** where changes in glycosylation have been associated with many states of health and disease providing prognostic and diagnostic information.


At Ludger, we have **decades of experience with analysing glycosylation** as part of our internal research project, but also, we provide our glycan analysis services¹ to world-leading biopharmaceutical and research organizations. We help customers around the globe characterize their drug's glycosylation and provide regulatory authorities with reliable, structured and detailed data.





The following are examples of how our **glycan analysis reports** are used:

- in **process optimisation**
- to support **regulatory submissions**
- batch **quality control** during the manufacturing of biopharmaceuticals

Our services include:

- **Sialic acid and monosaccharide analysis and quantitation**
- **N- and O-glycan profiling² and characterisation³**
- **High-throughput N-glycan screening⁴**
- **Custom method development and validation**
- **Method transfer, training and advisory services** to get glycoprofiling methods up and running in your laboratories




Sample types	
	Biopharmaceuticals Monoclonal antibodies (mAbs), Fc fusion proteins, vaccines, and glycoprotein hormones such as follicle stimulating hormone (FSH), and erythropoietin (EPO).
	Cells Mammalian cell lines, bacterial cell components
	Biological samples Patient's plasma, fluids, tissues and others
	Infected samples and cell lines COVID-19 patient samples and cell lines

¹ GMP-compliant modules are also available. ²This includes: HILIC-LC, MALDI-MS, and WAX-LC as well as site specific analysis. ³This includes: Exoglycosidase digestion followed by HILIC-UPLC and/or HILIC-UHPLC-FLR-ESI-MS/MS ⁴Receive a short report providing information on glycan relative quantitation and identification within two weeks.


Interested in our Glycan Analysis Services?

[Write to us](#) and book an initial meeting with our experts, they will guide you through the process and design a glycan analysis workflow tailored to the needs of your organization.


1 **Discuss your requirements** with our experts
We will sign a CDA/MSA if you required




2 Once you are satisfied with your Study Proposal & Quote, place your PO & **send us your samples**



3 **Sample Analysis**
We offer high-throughput and GMP-complaint sample analysis using state-of-the-art methodologies as well as custom solutions using chromatographic and mass spectrometric techniques and a combination thereof




4 **Data Analysis**
Data is analysed by our experts using specialised software and peer-reviewed to ensure high-quality standards



5 **Customised Report**
Whether your report is being used for a publication or regulatory submission, we will make sure it fulfils all your requirements





For more details, visit:

www.ludger.com

or email

info@ludger.com



Ludger Ltd UK headquarters
Culham Science Centre, Abingdon,
Oxfordshire OX14 3EB, United Kingdom
Tel:+44 1865 408554



Ludger China branch office
Plaza 66, 15/F, Tower 2, 1266 West
Nanjing Road, Jing'An District, Shanghai
200040, China